El European Commission, by Implementing Decision C (2026) 7475 of 19 October 2026, has designated rimonabant, the active substance in SFT-1, as an orphan medicinal product for the treatment of spinal cord injuries (Community register EU/3/26/3289). At Pharmaceutical Innovation Services, we are delighted to celebrate this important milestone for Sinfatin S.L.

A new step in the development of SFT-1

Spinal cord injury is a complex and rare neurological condition that can profoundly affect the mobility, independence and quality of life of those affected. The SFT-1 clinical programme aims to improve walking ability in people with spinal cord injury who retain the ability to walk.

SFT-1 contains low-dose rimonabant (5 mg), a cannabinoid CB1 receptor antagonist/inverse agonist that acts on the central nervous system. Results obtained to date, including those from the Phase 2b RIMOFATSCI-2 trial, point to its potential to improve motor function in people with incomplete thoracolumbar spinal cord injury.

The orphan medicinal product designation marks the beginning of a new stage in progressing towards a potential therapeutic alternative in an area of unmet medical need.

Our contribution

Pharmaceutical Innovation Services is a partner of Sinfatin and has been involved in the development of SFT-1 from the outset, including:

  • development of the active substance synthesis process;
  • development of the finished product in various doses and pharmaceutical forms;
  • regulatory strategy and documentation.

A shared milestone

We congratulate the Sinfatin team and the centres and organisations that have contributed to this achievement: Hospital Nacional de Parapléjicos de Toledo and its Foundation, Institut Guttmann, BIC Gipuzkoa, Medalchemy, Tecnalia, Laboratorium Sanitatis, CIDETEC and Fundación Teófilo Hernando.

En Servicios de Innovación Farmacéutica, we reaffirm our commitment to continuing our collaboration with Sinfatin to advance its projects and achieve new milestones together.

Would you like to learn more about SFT-1 and its clinical development? Find all the details on the Sinfatin website.